Beijing's Biopharma Sector Doubles in Size; Huaxia Yintai Aims to File NDA for Two Cell Therapy Drugs in 2026

　　【Pharmaceutical Network Industry Dynamics】The pharmaceuticals and health industry is one of the "twin engines" of Beijing's innovative development. Over the past decade, the overall scale of Beijing's pharmaceuticals and health industry has grown rapidly. Data shows that from 2014 to 2023, the overall scale of Beijing's pharmaceuticals and health industry increased from 402.8 billion yuan to 976.1 billion yuan, doubling in size.
 

Statistics show that the industrial scale of four key pharmaceutical areas in Beijing — Haidian District, Daxing District, Changping District, and the Economic Development Zone (EDZ) — accounts for nearly 80%. Multiple major industrial indicators have reached new highs. Industrial fixed-asset investment reached 12.4 billion yuan, more than quadrupling the figure from five years ago. The number of newly listed companies has increased by 67 (totaling 90), which is three times the previous total number of listed enterprises.
 

In the past decade, Beijing's pharmaceuticals and health industry has formed a "one south, one north" industrial cluster effect, with "China Medicine Valley" and "Life Valley" shining as twin stars from afar. As the core area of "Life Valley," Zhongguan Village Life Science Park boasts a complete industrial chain that connects research institutions, new startups, listed companies, clinical hospitals, and professional platforms, brimming with vitality.
 

Among them, Huaxia Yingtai (Beijing) Biotechnology Co., Ltd. is a specialized and innovative enterprise in Beijing and one of the key enterprises in Beijing's medical and health collaborative innovation action plan. It is reported that the company is developing a new generation of cell therapy products based on its self-innovated STAR-T technology platform using TCR-T technology, aiming to tackle solid tumors, hematological tumors, and autoimmune diseases.
 

Huaxia Yingtai(Beijing)Biotechnology Co., Ltd. indicated that the company is expected to submit new drug marketing applications for 1-2 cell therapy drugs in 2026. Currently, Huaxia Yingtai's product CD19/CD20 STAR-T Cell Injection was approved in September 2022 to conduct Phase I clinical research in China for relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL). The independently developed candidate product LILRB4 STAR-T, used for treating acute myeloid leukemia (AML), received "Orphan Drug" designation from the U.S. FDA in December 2022 and obtained IND approval in China to initiate Phase I clinical research in January 2024.
 

It is reported that, with the support of favorable policies, a number of innovative varieties with market potential have been emerging in Beijing. By 2023, 63 innovative medical devices (out of 251 in China) have been approved for marketing, accounting for one-fourth of the total in China, and 32 Class III AI medical devices (out of 84 in China) have been approved, accounting for over one-third of the total in China. The industry development shows a good trend of improving quality and efficiency.
 

In order to further promote the development of the pharmaceuticals and healthcare industry, the Beijing Municipal Medical Security Bureau and other departments recently issued the "Several Measures of Beijing Municipality to Support High-Quality Development of Innovative Pharmaceuticals (2024)." It mentioned utilizing the Beijing Pharmaceuticals and Healthcare Industry Investment Fund to attract social investment, driving the transformation of a group of strategically important and cutting-edge globally original technologies and products in Beijing. It supports industrial projects in fields such as innovative drugs and medical devices with significant potential output value, cell and gene therapy, and digital healthcare, helping them to settle in Beijing and achieve rapid product launches. It guides the financial system to provide venture capital and credit enhancement for start-up innovative pharmaceutical companies, encouraging more funds to invest early and in smaller enterprises. It comprehensively utilizes intellectual property and equity pledge financing, R&D loans, supply chain finance, and other products to support growing innovative pharmaceutical companies in expanding production, innovating R&D, and commercializing results. It optimizes traditional lending, cross-border investment and financing, investment banking M&A, and other integrated services to enhance the financial service compatibility for mature innovative pharmaceutical companies. Loans and discounts issued by relevant banks that meet the policy requirements of "Jingchuangrong" and "Jingchuangtong" will be given priority support.
 

In addition, Beijing will also advance the implementation of the third round of the "Beijing Action Plan for Accelerating the Coordinated Innovation of Medicine and Health (2024-2026)" this year. It aims to strengthen the synergy between innovative pharmaceuticals, medical devices, and the “three medicare” initiatives to promote Beijing’s innovation advantages. Efforts will be made to consolidate and expand the foundational sectors of the pharmaceutical and device industries. By fostering new quality productive forces in emerging fields such as cell and gene therapy, digital healthcare, and synthetic biology, Beijing seeks to create new competitive edges and accelerate the formation of a trillion-yuan-level industrial leap.
 

Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.